U.S. Markets closed

Viking Therapeutics, Inc. (VKTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.48-0.18 (-2.70%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.66
Open6.68
Bid6.51 x 1800
Ask6.52 x 3100
Day's Range6.46 - 6.78
52 Week Range3.26 - 8.36
Volume889,969
Avg. Volume1,247,066
Market Cap472.729M
Beta (5Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateOct 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.71
  • VKTX: Multiple Milestones Upcoming in 2021…
    Zacks Small Cap Research

    VKTX: Multiple Milestones Upcoming in 2021…

    By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update Management Provides Update on 2021 Outlook We recently spoke to the management team at Viking Therapeutics, Inc. (NASDAQ:VKTX), including CEO Brian Lian, regarding the outlook for the company in 2021 and anticipated milestones regarding the ongoing Phase 2b clinical trial of VK2809 in non-alcoholic steatohepatitis

  • Viking Therapeutics Announces Senior Management Team Appointments
    PR Newswire

    Viking Therapeutics Announces Senior Management Team Appointments

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced two key executive promotions. The company has named Greg Zante as chief financial officer and Marianne Mancini as chief operating officer.

  • Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference
    PR Newswire

    Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2021 Conference. The conference, which will take place January 11-14, 2021, is being conducted with a virtual format.